Astragalin_480-10-4_DataSheet_MedChemExpress

Naglazyme® (galsulfase)(Intravenous)Document Number: MH-0084 Last Review Date: 02/01/2022Date of Origin: 11/28/2011Dates Reviewed: 12/2011, 02/2013, 02/2014, 12/2014, 10/2015, 10/2016, 10/2017, 10/2018, 02/2019,02/2020, 02/2021, 02/2022I.Length of AuthorizationCoverage will be provided for 12 months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [NDC Unit]:•Naglazyme 5 mg vial: 23 vials per 7 daysB.Max Units (per dose and over time) [HCPCS Unit]:•115 billable units every 7 daysIII.Initial Approval Criteria 1Coverage is provided in the following conditions:•Patient is at least 5 years of age; AND•Documented baseline 12-minute walk test (12-MWT), 3-minute stair climb test (3-MSCT), and/or pulmonary function tests (e.g., FEV1, etc.); AND•Documented baseline value for urinary glycosaminoglycan (uGAG); ANDMucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) † Ф1,4,5•Patient has a definitive diagnosis of MPS VI as confirmed by the following:o Detection of pathogenic mutations in the ARSB gene by molecular genetic testing; ORo Arylsulfatase B (ASB) enzyme activity of <10% of the lower limit of normal in cultured fibroblasts or isolated leukocytes; AND▪Patient has normal enzyme activity of a different sulfatase (excluding patients with Multiple Sulfatase Deficiency [MSD]); AND▪Patient has an elevated urinary glycosaminoglycan (uGAG) level (i.e. dermatan sulfate or chondroitin sulfate) defined as being above the upper limit of normal bythe reference laboratory†FDA-approved indication(s); ‡Compendia recommended indication(s); ФOrphan DrugIV.Renewal Criteria 1,4,5Coverage can be renewed based on the following criteria:•Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified insection III; AND•Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: anaphylaxis and hypersensitivity reactions, immune-mediated reactions, acute respiratorycomplications associated with administration, acute cardiorespiratory failure, severeinfusion reactions, spinal or cervical cord compression, etc.; AND•Disease response with treatment as defined by improvement or stability from pre-treatment baseline by the following:o Reduction in uGAG levels; AND▪Improvement in or stability of 12-minute walk test compared (12-MWT); OR▪Improvement in or stability of 3-minute stair climb test (3-MSCT); OR▪Improvement in or stability of pulmonary function testing (e.g., FEV1, etc.)V.Dosage/Administration 1Indication DoseMucopolysaccharidosis VI(MPS VI, Maroteaux-Lamy Syndrome) 1 mg/kg administered as an intravenous (IV) infusion oncea weekVI.Billing Code/Availability InformationHCPCS Code:•J1458 – Injection, galsulfase, 1 mg; 1 billable unit = 1 mgNDC:•Naglazyme 5 mg per 5 mL solution; single-use vial: 68135-0020-xxVII.References1.Naglazyme [package insert]. Novato, CA; BioMarin Pharmaceutical Inc.; December 2019.Accessed January 2022.2.Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI.Pediatrics. 2007 Aug;120(2):405-18.3.Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief reviewand guidelines for treatment. Genet Mol Biol. 2010 Oct;33(4):589-604. Epub 2010 Dec 1.4.Vairo F, Federhen A, Baldo G, et al. Diagnostic and treatment strategies inmucopolysaccharidosis VI. Appl Clin Genet. 2015 Oct 30;8:245-55.5.Valaannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis VI. Orphanet J RareDis. 2010; 5: 5.6.Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy formucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled,multinational study of recombinant human N-acetylgalactosamine 4-sulfatase(recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. JPediatr. 2006 Apr;148(4):533-539.Appendix 1 – Covered Diagnosis CodesICD-10 ICD-10 DescriptionE76.29 Other mucopolysaccharidosesAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National CoverageDetermination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https:///medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/AMedicare Part B Administrative Contractor (MAC) JurisdictionsJurisdiction Applicable State/US Territory ContractorE (1) CA, HI, NV, AS, GU, CNMI Noridian Healthcare Solutions, LLCF (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Noridian Healthcare Solutions, LLC5 KS, NE, IA, MO Wisconsin Physicians Service Insurance Corp (WPS)6 MN, WI, IL National Government Services, Inc. (NGS)H (4 & 7) LA, AR, MS, TX, OK, CO, NM Novitas Solutions, Inc.8 MI, IN Wisconsin Physicians Service Insurance Corp (WPS) N (9) FL, PR, VI First Coast Service Options, Inc.J (10) TN, GA, AL Palmetto GBA, LLCM (11) NC, SC, WV, VA (excluding below) Palmetto GBA, LLCNovitas Solutions, Inc.L (12) DE, MD, PA, NJ, DC (includes Arlington &Fairfax counties and the city of Alexandria in VA)K (13 & 14) NY, CT, MA, RI, VT, ME, NH National Government Services, Inc. (NGS)15 KY, OH CGS Administrators, LLC。

药物分析杂志　杂质的结构式Structural formulas of genotoxic impurities根据欧洲药事管理局和美国食品药品管理局求［8-9］，基因毒性杂质的毒理学关注阈threshold of toxicological concern，TTC）限度为1.5 阿加曲班每日最高服用剂量为60 mg，因此，阿加曲班中杂质A、B、C和D的限度均为25 μg·g-1，总限度值也是25 μg·g-1。

现有文献尚未见阿加曲班基因毒性杂质测定的报道，因此，有必要建立阿加曲班中杂质的检测方法。

喹啉磺酸类杂质主要的检测方法是液相）［10-11］。

LC法灵敏度较低，多组分分析有时无法有效分离；液相色谱-质谱联用技术具有分析速度快、结果准确可靠的特点，可以满足痕量毒性杂质检测的要求［12-16］。

本文建立了相色谱-串联质谱法（UPLC-MS）测定阿加曲班中4种基因毒性杂质，并进行了相应的方法学验证，为阿加曲班的工艺和质量控制提供参考依据。

1　仪器与试药Acquity超高效液相色谱仪（Waters公司）TQ串联质谱仪（Waters公司），质谱软件为4.1工作站；XPE105电子天平（0.01 mg托利多公司）；Milli-Q超纯水器（Millipore ACQUITY UPLC BEH C18色谱柱（100 mm1.7 μm；填料：十八烷基硅烷键合硅胶；司）。

阿加曲班原料药、杂质A~D的对100%）均由北京悦康科创医药科技股份有限公司提供；甲醇、乙腈、甲酸均为色谱级（默克公司）Journal of Pharmaceutical Analysis 药物分析杂志Chinese2　杂质对照品溶液总离子流图Fig．2　Total ion chromatograms of genotoxic impurities reference substance solution2.4　检测下限和定量下限取杂质A~C对照品储备液，逐级稀释，直至各杂质峰峰高约为基线噪音的10 倍，测得杂质A、B 的定量下限分别为5.0、0.125、0.25 ng·mL-1；连续进样6 次，杂质A、B、C峰面积的RSD分别为2.6% 2.4%和1.9%，表明定量下限具有良好的精密度。

谷胱甘肽-琼脂糖凝胶4B （GST 标签纯化树脂）说明书货号：P2020规格：5mL/10mL/25mL/50mL保存：4℃保存，有效期至少一年。

产品简介：pGEX 载体表达的外源蛋白与谷胱甘肽S-转移酶融合，因此可以通过谷胱甘肽-琼脂糖亲和层析进行纯化。

GSTs 是一类以谷胱甘肽（γ-谷氨酰半胱氨酰甘氨酸）作为底物，通过形成硫醇尿酸失活毒性小分子的酶。

由于GST 对底物的亲和力是亚毫摩尔级的，因此谷胱甘肽固化于琼脂糖形成的亲和层析树脂对GST 及其融合蛋白的纯化效率很高。

可以用含游离谷胱甘肽的缓冲液洗脱结合GST 融合蛋白。

树脂用3mol/L NaCl 的缓冲液再生。

谷胱甘肽琼脂糖对GST 融合蛋白的结合能力很强（每毫升柱床体积的树脂能结合8毫克融合蛋白）。

特性:粒度：45-165µm流速：75cm/h 工作PH ：4-10耐压：0.3Mpa载量：＞5mg 谷胱甘肽S-转移酶使用说明：谷胱甘肽树脂的处理:1.轻轻颠倒盛有谷胱甘肽-琼脂糖树脂的容器，将树脂混成匀浆。

2.取部分匀浆放入15mL 聚丙烯管（每100mL 细菌培养物大约需要2mL 匀浆）。

3.4℃500g 离心5分钟，小心去掉上清。

4.在树脂中加入10倍柱床体积预冷的PBS ，颠倒数次混匀，4℃500g 离心5分钟，小心去掉上清。

5.每毫升树脂加入1毫升冷的PBS ，制成50%匀浆，颠倒数次，混合均匀，悬液冰上放置待用。

制备细胞抽提物：6.每100毫升培养物的细胞沉淀重悬于4mL PBS 缓冲液中。

7.加入溶菌酶至终浓度为1mg/mL,冰上放置30分钟。

8.用针筒将10mL 浓度为0.2%的TritonX-100强行注入黏稠的细胞裂解物中，剧烈振动数次混匀。

加入DNase 和RNase 至终浓度5ug/mL,4℃振动温育10分钟，4℃3000g 离心30分钟，去除不溶性细胞碎片，上清转移到一只新管中，加入DTT 至终浓度1mmol/L 。

SDSE所有详细试剂配方SDSE（Sodium dodecyl sulfate-electrolyte system）是一种常用的聚丙烯酰胺凝胶电泳缓冲液，主要用于蛋白质电泳分离。

SDSE的制备是根据一定的配方进行的，下面是SDSE的详细试剂配方：1.氯化钠（NaCl）：18.3g溶解在1L去离子水中2.磷酸二氢钠（NaH2PO4）：3.5g溶解在1L去离子水中3. 溴酚蓝（Bromophenol Blue）：0.25g溶解在10mL水中4. SDS（Sodium Dodecyl Sulfate）：10g溶解在1L去离子水中5. 甘油（Glycerol）：10mL溶解在100mL去离子水中以上是SDSE的基础配方，下面是其制备步骤：1.将NaCl和NaH2PO4溶解在分别容量为1L的去离子水中，用磁力搅拌器搅拌均匀。

2.分别将溶解好的NaCl和NaH2PO4溶液倒入大容量烧杯中，混合均匀。

3.在pH计的帮助下调节缓冲液的pH值，使其在6.8-7.0之间。

4.加入溴酚蓝溶液，此时溴酚蓝的浓度为0.0025%，用磁力搅拌器搅拌均匀。

5.加入SDS溶液，用磁力搅拌器搅拌均匀。

注意，加入SDS时要小心，避免溅出。

6.最后加入甘油溶液，搅拌均匀。

甘油的添加主要是为了增加样品的密度，使其在凝胶中下沉更快。

SDSE的配方比较简单，主要成分包括NaCl、NaH2PO4、溴酚蓝、SDS和甘油。

其中，NaCl和NaH2PO4是缓冲液的主要组成部分，用于维持适当的离子强度和pH值；溴酚蓝用于着色样品，方便观察电泳结果；SDS主要起到断开蛋白质的二级结构和线性化作用；甘油则用于增加样品密度，使其在凝胶中下沉更快。

通过恰当的配方和制备步骤，可以获得高质量的SDSE缓冲液，用于蛋白质电泳分离和分析。

但需要注意的是，不同实验目的和要求可能需要微调配方中一些成分的浓度，因此在具体实验过程中，可以根据需要进行相应的调整。

Intended Use:For In Vitro Diagnostic UseHeat induced antigen retrieval of formalin-fixed paraffin-embedded (FFPE) tissues for immunohistochemistry (IHC) procedures. The clinical interpretation of any staining or its absence should be complimented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.Summary & Explanation:Diva Decloaker is a heat retrieval solution that is compatible with virtually all antibodies and eliminates the need for multiple buffers including citrate buffer, EDTA or high pH tris buffers. Antibody titers are doubled and tripled when compared to citrate buffer, pH 6.0. Diva Decloaker incorporates Assure™ tech nology, a color-coded high temperatures pH indicator solution. The end-user is assured by visual inspection that the solution is at the correct dilution and pH. This product is specially formulated for superior pH stability at high temperatures and will help prevent the possibility of losing pH sensitive antigens. Diva Decloaker is non-toxic, non-flammable, odorless and sodium azide and thimerosal free.Known Applications:Immunohistochemistry (formalin-fixed paraffin-embedded tissues) Supplied As:100mlDiva Decloaker, 10X concentrate (DV2004LX)500mlDiva Decloaker, 10X concentrate (DV2004MX)Materials and Reagents (Needed But Not Provided): Microscope slides, positively chargedDesert Chamber* (Drying oven)Positive and negative tissue controlsXylene (Could be substituted with xylene substitute*)Ethanol or reagent alcoholDecloaking Chamber* (Pressure cooker)Deionized or distilled waterWash buffer*(TBS/PBS)Enzyme digestion*Avidin-Biotin Blocking Kit*(Labeled Streptavidin Kits Only) Peroxidase block*Protein block*Primary antibody*Negative control reagents*Detection kits*Detection components*Chromogens*Hematoxylin*Bluing reagent*Mounting medium** Biocare Medical Products: Refer to a Biocare Medical catalog for further information regarding catalog number and ordering information. Certain reagents listed above are based on specific application and detection system used. Storage and Stability:Store at room temperature. Do not use after expiration date printed on vial. If reagents are stored under conditions other than those specified in the package insert, they must be verified by the user. Diluted reagents should be used promptly; any remaining reagent should be stored at room temperature.Protocol Recommendations:1. Deparaffinize tissues and hydrate to water. If necessary, block for endogenous peroxidase and wash in DI water.2. Dilute concentrated Diva Decloaker at a ratio of 1:10 (1 ml Diva to 9 ml of deionized water).3. Place slides into 1X retrieval solution in a slide container (e.g. Coplin Jar, Tissue -Tek™ staining dish or metal slide canister).4. Retrieve sections under pressure using Biocare's Decloaking Chamber. Follow the recommendations on the antibody data sheet and Decloaking Chamber User Manual.5. Check solution for appropriate color change. (See Technical Note #1)6. Gently rinse by gradually adding DI water to the solution, then remove slides and rinse with DI water.Technical Notes:1. Concentrated Diva Decloaker is a bright yellow color. RTU or 1X solution is a pale yellow color. When the solution reaches 80-125°C, the solution turns yellow and indicates that the high temperature solution is at correct pH. Should the pH rise above 7.0, the solution turns a fuschia red color. Should the pH drop too low, thesolution turns a pink color.2. If using Biocare’s Desert Chamber Pro (a programmable turbo-action drying oven), dry sections at 25ºC overnight or at 37ºC for 30-60 minutes and then dry slides at 60ºC for 30 minutes.3. Use positive char ged slides (use Biocare’s Kling-On HIER Slides) and cut tissues at 4-5 microns. Do not use any adhesives in the water bath. Poor fixation and processing of tissues will cause tissue sections to fall off the slides, especially fatty tissues such as breast. Tissues should be fixed a minimum of 6-12 hours.4. Protocol time and temperatures for HIER can vary depending on the Decloaking Chamber model used. Please refer to the relevant Decloaking Chamber manual for appropriate protocol times and temperatures.Limitations:The protocols for a specific application can vary. These include, but are not limited to: fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, asresults may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests.Catalog Number: DV2004 LX, MX Description: 100, 500 ml, concentrateQuality Control:Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2). CLSI Wayne, PA, USA (). 2011 Precautions:1. This product is not classified as hazardous. The preservative used in this reagent is Proclin 300 and the concentration is less than 0.25%. Overexposure to Proclin 300 can cause skin and eye irritation and irritation to mucous membranes and upper respiratory tract. The concentration of Proclin 300 in this product does not meet the OSHA criteria for a hazardous substance. Wear disposable gloves when handling reagents.2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water.3. Microbial contamination of reagents may result in an increase in nonspecific staining.4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.5. Do not use reagent after the expiration date printed on the vial.6. The SDS is available upon request and is located at /.7. Consult OSHA, federal, state or local regulations for disposal of any toxic substances. Proclin is a trademark of Rohm and Haas Company, or of its subsidiaries or affiliates.Troubleshooting:Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.。

小鼠β半乳糖苷酶(βGAL)ELISA试剂盒使用说明书本本试剂仅供研究使用标本：血清或血浆本试剂仅供研究使用目的：本试剂盒用于测定人血清，血浆及相关液体样本中β半乳糖苷酶(βGAL)的含量。

试验原理：βGAL试剂盒是固相夹心法酶联免疫吸附实验（ELISA）.已知βGAL浓度的标准品、未知浓度的样品加入微孔酶标板内进行检测。

先将βGAL和生物素标记的抗体同时温育。

小鼠β半乳糖苷酶ELISA试剂盒洗涤后，加入亲和素标记过的HRP。

再经过温育和洗涤，去除未结合的酶结合物，然后加入底物A、B，和酶结合物同时作用。

产生颜色。

颜色的深浅和样品中βGAL的浓度呈比例关系。

试剂盒组成：自备材料蒸馏水。

加样器：5ul、10ul、50ul、100ul、200、500ul、1000ul。

振荡器及磁力搅拌器等。

安全性避免直接接触终止液和底物A、B。

一旦接触到这些液体，请尽快用水冲洗。

实验中不要吃喝、抽烟或使用化妆品。

不要用嘴吸取试剂盒里的任何成份。

操作注意事项试剂应按标签说明书储存，使用前恢复到室温。

稀稀过后的标准品应丢弃，不可保存。

实验中不用的板条应立即放回包装袋中，密封保存，以免变质。

不用的其它试剂应包装好或盖好。

不同批号的试剂不要混用。

保质前使用。

使用一次性的吸头以免交叉污染，吸取终止液和底物A、B液时，避免使用带金属部分的加样器。

使用干净的塑料容器配置洗涤液。

使用前充分混匀试剂盒里的各种成份及样品。

洗涤酶标板时应充分拍干，不要将吸水纸直接放入酶标反应孔中吸水。

底物A应挥发，避免长时间打开盖子。

底物B对光敏感，避免长时间暴露于光下。

避免用手接触，有毒。

实验完成后应立即读取OD值。

加入试剂的顺序应一致，以保证所有反应板孔温育的时间一样。

按照说明书中标明的时间、加液的量及顺序进行温育操作。

样品收集、处理及保存方法血清-----操作过程中避免任何细胞刺激。

使用不含热原和内毒素的试管。

收集血液后，1000×g离心10分钟将血清和红细胞迅速小心地分离。

仅仅研究于生命科学，不适合在诊断过程使用只能在体外使用地高辛DNA标记和检测试剂盒1和NBT/BCIP一起用于颜色检测通过酶联免疫法采用地高辛-dUTP进行随机引物DNA标记，碱性标记和检测货号：11 745 832 910此试剂盒储存条件-15o C—-25o C此试剂盒可对10ng-3ugDNA进行12次标记反应可检测100cm2面积的杂交膜24张指导手册2009.11版1前言1.1内容表1前言 (2)1.1内容表 (2)1.2试剂盒内容 (3)2简介 (5)2.1产品概述 (5)3步骤和所需材料 (8)3.1开始之前 (8)3.2地高辛DNA标记 (9)3.3 标记效率的测定 (11)3.4 DNA 的转移和固定 (14)3.5杂交 (16)3.6免疫检测 (18)3.7 DNA印记的洗脱和再杂交 (20)4结果 (21)4.1典型的结果 (21)5附录 (23)5.1故障排除 (23)5.2引用 (24)5.3订购信息 (25)1.2 试剂盒内容附加仪器与所需试剂除了上表中列出的试剂外，你必须准备一些溶液。

在下表中，你可以找到不同操作程序需要准备的设备概要。

*标记的产品可以从Roche Applied Science 获得2 介绍2.1 产品概况实验原则此试剂盒采用地高辛（DIG），一种甾类半抗原，去标记DNA探针从而通过酶免疫分析应用地高辛标记DNA探针可以用于：所有类型的滤膜杂交总基因组DNA中单拷贝基因的检测，甚至对于高度复杂的生物也可以进行检测，如人，大麦和小麦。

样品材料至少100bp的DNA片段线性的质粒，cos质粒或者λDNA超螺旋的DNA实验时间此表格列出了每一步实验所需的反应时间检测数量一个试剂盒足够用于：不超过3ug的模板DNA的12个标准的标记反应和100cm2有24个斑点的检测质量控制根据操作步骤中的描述，对未标记的对照品DNA（PBR328）进行标记，0.1pg同源DNA 在点杂交中通过16h的显色来检测（1pg同源DNA可以通过1小时的显色进行检测）。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Mar.-25-2019Print Date:Mar.-25-20191. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :TMA-DPHCatalog No. :HY-D0986CAS No. :115534-33-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C28H31NO3SMolecular Weight:461.62CAS No. :115534-33-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: -20°C, protect from lightShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2019 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

分子量448.38溶解性（25°C ）DMSO 10 mM 分子式C H O Water <1 mM CAS 号480-10-4Ethanol <1 mM储存条件3年 -20°C 粉末状生物活性体外研究：不溶于20μM 的黄芪素抑制Toll 样受体4（TLR4）的细胞诱导和LPS 增强的ROS 产生。

LPS 和H2O2诱导上皮嗜酸性粒细胞趋化因子-1表达，被黄芪素阻断。

LPS 激活并诱导上皮细胞中p22phox 和p47phox 的PLCγ1，PKCβ2和NADPH 氧化酶亚基，并通过黄芪素或TLR4抑制拮抗嗜酸细胞活化趋化因子-1诱导降低这种活化和诱导。

通过向上皮细胞中加入黄芪胶来抑制H 2 O 2上调的JNK 和p38MAPK 的磷酸化，而这种化合物增强Akt 和ERK 的上皮激活。

H2O2和LPS 促进上皮细胞凋亡，伴随着核凝聚或胱天蛋白酶-3激活，其被黄芪素钝化。

黄芪素以mMECs 的剂量依赖性方式抑制肿瘤坏死因子α，白细胞介素6和一氧化氮的表达。

体内研究：用脂多糖（LPS ）（剂量范围：5-40mg / kg ）腹膜内（i.p.）注射小鼠。

用黄芪素预处理可以改善致死性内毒素血症期间的存活，减轻脂多糖诱导的急性肺损伤鼠模型中的炎症反应。

不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA 指南）小鼠大鼠兔豚鼠仓鼠狗重量 (kg)0.020.15 1.80.40.0810体表面积 (m )0.0070.0250.150.050.020.5K 系数36128520动物 A (mg/kg) = 动物 B (mg/kg) ×动物 B 的K 系数动物 A 的K 系数例如，依据体表面积折算法，将白藜芦醇用于小鼠的剂量22.4 mg/kg 换算成大鼠的剂量，需要将22.4 mg/kg 乘以小鼠的K 系数（3），再除以大鼠的K 系数（6），得到白藜芦醇用于大鼠的等效剂量为11.2 mg/kg 。